Shots:

• The approval is based on P-III BLOCKSTONE study assessing a single dose of Xofluza vs PBO in household members who were living with someone with influenza confirmed by a rapid influenza diagnostic test
• Results: The proportion of household members aged ≥12yrs. who developed influenza (1% vs 13%)- well-tolerated with no new safety signals
• Xofluza is the first single-dose influenza medicine approved to prevent influenza for those who have had contact with an infected person. Roche also plans to file sNDA for Xofluza as a treatment for acute uncomplicated influenza in pediatric patients (1-12yrs.) and for the prevention of influenza in the same age group who have been exposed to influenza

 ­ Ref: GlobeNewswire | Image: Roche